There is limited information available to date regarding the clinical significance of different classes of HDAC expression in ovarian adenocarcinomas and in particular class II members, even though the role of HDAC inhibitors in the treatment of ovarian adenocarcinoma is being thoroughly discussed [11]. Here, HDAC9 is linked to ovarian adenocarcinoma.